Retatrutide LY3437943: Understanding the Drug Code

If you have been researching retatrutide, you have likely encountered the code "LY3437943" in scientific papers, clinical trial databases, and news articles. LY3437943 is Eli Lilly's internal research designation for the same molecule that the world now knows as retatrutide — the investigational triple-agonist drug that produced an average of 24.2% body weight loss in Phase 2 trials (Jastreboff et al., NEJM 2023). Understanding what this code means and how pharmaceutical naming works can help you better navigate the growing body of research on this drug.

Decoding LY3437943

Every investigational drug begins its life with an internal company code. For Eli Lilly, all compounds receive an "LY" prefix followed by a unique number:

• LY = Eli Lilly and Company (company identifier)
• 3437943 = Sequential compound number assigned during drug discovery

This system allows Lilly to track thousands of compounds through their research pipeline. Most LY-coded compounds never make it past early testing. LY3437943 is one of the rare molecules that has advanced all the way to Phase 3 clinical trials.

The Three Stages of Drug Naming

A pharmaceutical drug typically goes through three naming stages during its lifecycle:

For context, here is how this played out with tirzepatide, Lilly's other major weight loss drug:

• Company code: LY3298176
• Generic name: tirzepatide
• Brand names: Mounjaro (for diabetes), Zepbound (for weight loss)

Retatrutide will likely follow the same pattern — receiving one or more brand names when approved for specific indications.

What "Retatrutide" Tells Us

The generic name "retatrutide" is not random. The World Health Organization (WHO) uses systematic naming conventions called International Nonproprietary Names (INNs) that encode information about a drug's mechanism:

• "-tide" suffix: Indicates the molecule is a peptide (a chain of amino acids)
• "-glutide" / "-trutide" stem: Relates to the GLP-1 receptor agonist class
• "reta-" prefix: Unique identifier distinguishing it from other drugs in the same class

Compare this to related drug names: semaglutide, tirzepatide, retatrutide. The naming patterns reflect shared pharmacological roots while distinguishing each drug's unique identity.

Using the Code to Find Research Data

Knowing both names — LY3437943 and retatrutide — is important for thorough research:

ClinicalTrials.gov

Search for either "LY3437943" or "retatrutide" to find all registered trials. Earlier trials may use the LY code exclusively, while newer TRIUMPH trials list both names. Using both search terms ensures you do not miss any trials.

PubMed and Scientific Literature

The landmark Phase 2 paper (Jastreboff et al., NEJM 2023) uses both "retatrutide" and "LY3437943" in its text. Searching PubMed for either term will find the published research. Older preclinical studies may only reference LY3437943.

Conference Presentations

Scientific conferences like the American Diabetes Association (ADA) and Obesity Week have featured presentations on retatrutide/LY3437943. Conference abstracts may use either name.

Other Notable Drug Codes in Weight Loss

Understanding the code system helps you track other drugs in development:

Available Medications Today

While LY3437943/retatrutide moves through Phase 3 trials, proven GLP-1 medications are available now through TRIMI:

• Compounded semaglutide: $125/month
• Compounded tirzepatide: $125/month

Learn more about how TRIMI works and start treatment with proven medications today.